Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Harvard
Biotech
HHS division refers Harvard for potential debarment
If Harvard undergoes debarment, the university would be blocked from business relations with any federal agency for a specified time frame.
Eric Sagonowsky
Sep 29, 2025 4:59pm
Massachusetts most impacted by NIH research cuts: Grant Witness
Sep 18, 2025 9:38am
Roche to house its CVRM research work at new Boston hub
Mar 7, 2025 9:40am
Sanofi-backed biotech hauls in $70M series A for covalent bonds
Oct 14, 2022 6:30am
The top 10 global R&D institutes of 2021
Aug 22, 2022 3:00am
Fat could hold key to stem cell treatment for Parkinson's
May 31, 2022 7:30am
